Identification and cloning of neoantigen-specific T cells for GBM immunotherapy

用于 GBM 免疫治疗的新抗原特异性 T 细胞的鉴定和克隆

基本信息

  • 批准号:
    10375387
  • 负责人:
  • 金额:
    $ 40.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-04-01 至 2024-03-31
  • 项目状态:
    已结题

项目摘要

SUMMARY/ABSTRACT The lack of effective glioblastoma treatments poses a significant health problem and highlights the need for novel and innovative approaches. Immunotherapy is an appealing strategy because of the potential ability for immune cells to traffic to and destroy infiltrating tumor cells in the brain. New information suggests that patients mounting immune responses after immunotherapy preferentially recognize novel neoantigens created by tumor-specific mutations. Our data, and that from other immunotherapeutic strategies for patients with cancer, suggest that the vast majority of tumor-specific T cells induced by such personalized, patient-specific immunotherapies do NOT recognize well-characterized, known antigens. Such information is consistent with recent data from other immune-responsive cancers, such as melanoma, in which the percentage of tumor-specific T cells recognizing known antigens was less than 1%. In order to design the most effective immunotherapeutic strategies for glioblastoma, we believe that it is critical to understand which antigens tumor-specific T cells recognize in this disease. Our hypothesis is that glioblastoma patients treated with immunotherapy will mount anti-tumor immune responses against specific mutations and splice variants in their individual tumors. Similarly, our other recent findings strongly suggest that the addition of PD-1 antibody (mAb) blockade to DCVax enhances both the intra-tumoral CD8+ T cell response and clinical benefit in pre-clinical studies. Furthermore, the timing of PD-1 mAb blockade is immunologically relevant; our unpublished, recent clinical trial results highlight how the neoadjuvant (prior to surgery) treatment with PD-1 mAb blockade induces enhanced anti-tumor immune responses and clinical benefit. We hypothesize that the addition of PD-1 mAb blockade should amplify the neoantigen-specific T cell response induced by DC vaccination, both in the blood and the tumor. To test these important questions, In Aim 1, we will develop a new bioinformatics pipeline to predict neoantigens that arise specifically from the types of genetic alterations that occur in GBM. In Aim 2, will create immunocompetent murine glioma models to test the importance of neoantigens. Finally, in Aim 3, we will identify neoantigen-specific T cells from both the TIL population and peripheral blood of GBM patients treated with immunotherapy. These studies span the continuum of translational research in brain tumor immunotherapy and will likely provide informative new insights for the development of new, rational immune-based strategies for brain tumor patients.
总结/摘要 缺乏有效的胶质母细胞瘤治疗构成了一个重大的健康问题,并强调了对新的治疗方法的需要。 和创新的方法。免疫治疗是一种有吸引力的策略,因为免疫治疗具有潜在的免疫功能。 细胞进入并破坏大脑中浸润的肿瘤细胞。新的信息表明, 免疫治疗后的免疫应答优先识别由肿瘤特异性抗体产生的新抗原, 突变。我们的数据以及其他癌症患者免疫策略的数据表明, 绝大多数肿瘤特异性T细胞由这种个性化的患者特异性免疫疗法诱导, 不识别特征明确的已知抗原。这些信息与最近的数据一致, 其他免疫应答癌症,如黑素瘤,其中肿瘤特异性T细胞的百分比 对已知抗原的识别率低于1%。为了设计出最有效的免疫系统 我们认为,关键是要了解哪些抗原肿瘤特异性T细胞 认识到这种疾病。我们的假设是,接受免疫治疗的胶质母细胞瘤患者 针对其个体中的特定突变和剪接变体产生抗肿瘤免疫应答, 肿瘤的同样,我们最近的其他研究结果强烈表明,PD-1抗体(mAb)阻断剂的加入, 在临床前研究中,DCVax增强了肿瘤内CD 8 + T细胞应答和临床益处。 此外,PD-1 mAb阻断的时机与免疫学相关;我们最近未发表的临床试验 结果强调了PD-1 mAb阻断的新辅助治疗(手术前)如何诱导增强的 抗肿瘤免疫应答和临床益处。我们假设PD-1 mAb阻断剂的加入 应该放大DC疫苗接种诱导的新抗原特异性T细胞应答, 还有肿瘤为了测试这些重要的问题,在目标1中,我们将开发一个新的生物信息学管道, 预测新抗原,特别是从GBM中发生的遗传变异类型产生的。在目标2中,将 建立免疫活性鼠神经胶质瘤模型以测试新抗原的重要性。在目标3中,我们将 从接受治疗的GBM患者的TIL群体和外周血中鉴定新抗原特异性T细胞 免疫疗法这些研究跨越了脑肿瘤免疫治疗转化研究的连续统一体 并可能为开发新的,合理的基于免疫的策略提供信息丰富的新见解, 脑肿瘤患者

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Robert M Prins其他文献

Robert M Prins的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Robert M Prins', 18)}}的其他基金

Neoadjuvant checkpoint blockade for recurrent glioblastoma
新辅助检查点阻断治疗复发性胶质母细胞瘤
  • 批准号:
    10343478
  • 财政年份:
    2022
  • 资助金额:
    $ 40.25万
  • 项目类别:
Neoadjuvant checkpoint blockade for recurrent glioblastoma
新辅助检查点阻断治疗复发性胶质母细胞瘤
  • 批准号:
    10661485
  • 财政年份:
    2022
  • 资助金额:
    $ 40.25万
  • 项目类别:
Identification and cloning of neoantigen-specific T cells for GBM immunotherapy
用于 GBM 免疫治疗的新抗原特异性 T 细胞的鉴定和克隆
  • 批准号:
    9903258
  • 财政年份:
    2019
  • 资助金额:
    $ 40.25万
  • 项目类别:
Identification and cloning of neoantigen-specific T cells for GBM immunotherapy
用于 GBM 免疫治疗的新抗原特异性 T 细胞的鉴定和克隆
  • 批准号:
    10599231
  • 财政年份:
    2019
  • 资助金额:
    $ 40.25万
  • 项目类别:
Developmental Research Program
发展研究计划
  • 批准号:
    9983051
  • 财政年份:
    2017
  • 资助金额:
    $ 40.25万
  • 项目类别:
Project 1: Targeting immunotherapy-induced resistance with DC vaccination and PD-1/CSF-1R inhibition
项目 1:通过 DC 疫苗接种和 PD-1/CSF-1R 抑制来针对免疫治疗引起的耐药性
  • 批准号:
    10673749
  • 财政年份:
    2017
  • 资助金额:
    $ 40.25万
  • 项目类别:
Developmental Research Program
发展研究计划
  • 批准号:
    10225554
  • 财政年份:
    2017
  • 资助金额:
    $ 40.25万
  • 项目类别:
Developmental Research Program
发展研究计划
  • 批准号:
    10673782
  • 财政年份:
    2017
  • 资助金额:
    $ 40.25万
  • 项目类别:
Optimizing Induction Conditions for Immunotherapeutic CTL
优化免疫治疗 CTL 的诱导条件
  • 批准号:
    8704325
  • 财政年份:
    2010
  • 资助金额:
    $ 40.25万
  • 项目类别:
CNS Anti-tumor immunity induced by dendritic cell vaccination and TLR agonists
树突状细胞疫苗和 TLR 激动剂诱导的 CNS 抗肿瘤免疫
  • 批准号:
    7754039
  • 财政年份:
    2007
  • 资助金额:
    $ 40.25万
  • 项目类别:

相似海外基金

The earliest exploration of land by animals: from trace fossils to numerical analyses
动物对陆地的最早探索:从痕迹化石到数值分析
  • 批准号:
    EP/Z000920/1
  • 财政年份:
    2025
  • 资助金额:
    $ 40.25万
  • 项目类别:
    Fellowship
Animals and geopolitics in South Asian borderlands
南亚边境地区的动物和地缘政治
  • 批准号:
    FT230100276
  • 财政年份:
    2024
  • 资助金额:
    $ 40.25万
  • 项目类别:
    ARC Future Fellowships
The function of the RNA methylome in animals
RNA甲基化组在动物中的功能
  • 批准号:
    MR/X024261/1
  • 财政年份:
    2024
  • 资助金额:
    $ 40.25万
  • 项目类别:
    Fellowship
Ecological and phylogenomic insights into infectious diseases in animals
对动物传染病的生态学和系统发育学见解
  • 批准号:
    DE240100388
  • 财政年份:
    2024
  • 资助金额:
    $ 40.25万
  • 项目类别:
    Discovery Early Career Researcher Award
Zootropolis: Multi-species archaeological, ecological and historical approaches to animals in Medieval urban Scotland
Zootropolis:苏格兰中世纪城市动物的多物种考古、生态和历史方法
  • 批准号:
    2889694
  • 财政年份:
    2023
  • 资助金额:
    $ 40.25万
  • 项目类别:
    Studentship
Using novel modelling approaches to investigate the evolution of symmetry in early animals.
使用新颖的建模方法来研究早期动物的对称性进化。
  • 批准号:
    2842926
  • 财政年份:
    2023
  • 资助金额:
    $ 40.25万
  • 项目类别:
    Studentship
Study of human late fetal lung tissue and 3D in vitro organoids to replace and reduce animals in lung developmental research
研究人类晚期胎儿肺组织和 3D 体外类器官在肺发育研究中替代和减少动物
  • 批准号:
    NC/X001644/1
  • 财政年份:
    2023
  • 资助金额:
    $ 40.25万
  • 项目类别:
    Training Grant
RUI: Unilateral Lasing in Underwater Animals
RUI:水下动物的单侧激光攻击
  • 批准号:
    2337595
  • 财政年份:
    2023
  • 资助金额:
    $ 40.25万
  • 项目类别:
    Continuing Grant
RUI:OSIB:The effects of high disease risk on uninfected animals
RUI:OSIB:高疾病风险对未感染动物的影响
  • 批准号:
    2232190
  • 财政年份:
    2023
  • 资助金额:
    $ 40.25万
  • 项目类别:
    Continuing Grant
A method for identifying taxonomy of plants and animals in metagenomic samples
一种识别宏基因组样本中植物和动物分类的方法
  • 批准号:
    23K17514
  • 财政年份:
    2023
  • 资助金额:
    $ 40.25万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了